The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis
| العنوان: | The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis |
|---|---|
| المؤلفون: | Ping Wang, Chris H. Polman, Jeffrey A. Cohen, Andrew D. Goodman, Eva Havrdova, Richard A. Rudick, Arun V. Krishnan, James Potts |
| المساهمون: | Neurology, NCA - Neuroinflamation |
| المصدر: | Cohen, J A, Krishnan, A V, Goodman, A D, Potts, J, Wang, P, Havrdova, E, Polman, C & Rudick, R A 2014, ' The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis ', JAMA Neurology, vol. 71, no. 11, pp. 1386-1393 . https://doi.org/10.1001/jamaneurol.2014.1895Test JAMA Neurology, 71(11), 1386-1393. American Medical Association |
| بيانات النشر: | American Medical Association (AMA), 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Multiple Sclerosis, Adolescent, Walking, Antibodies, Monoclonal, Humanized, law.invention, Young Adult, Physical medicine and rehabilitation, Natalizumab, Quality of life, Randomized controlled trial, law, Task Performance and Analysis, medicine, Humans, Retrospective Studies, Expanded Disability Status Scale, business.industry, Multiple sclerosis, Interferon beta-1a, Interferon-beta, Middle Aged, medicine.disease, Clinical trial, Preferred walking speed, Quality of Life, Physical therapy, Drug Therapy, Combination, Female, Neurology (clinical), business, medicine.drug |
| الوصف: | Walking impairment, a common clinical manifestation of multiple sclerosis (MS), is often measured in clinical practice and clinical trials using the Timed 25-Foot Walk (T25-FW).To evaluate the relationship between walking speed measured by the T25-FW and the Physical Component Summary (PCS) score of the 36-Item Short Form Health Survey (SF-36) to better understand the clinical meaning of T25-FW walking speed in MS.We retrospectively analyzed data from 3 clinical trials (Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis [AFFIRM], Safety and Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing-Remitting Multiple Sclerosis [SENTINEL], and International MS Secondary Progressive Avonex Controlled Trial [IMPACT]) that included T25-FW and SF-36 scores as outcomes in patients with MS. Patients had secondary-progressive MS and an Expanded Disability Status Scale score of 3.5 to 6.5 or relapsing-remitting MS and an Expanded Disability Status Scale score of 0 to 5.0.We used Spearman rank correlation and Pearson product moment correlation (r ) and descriptive statistics to evaluate retrospectively the relationship between the SF-36 PCS score and T25-FW walking speed at baseline and the 2-year changes from baseline.Among all 2549 patients from the 3 trials, walking speed and SF-36 PCS score at baseline were significantly correlated (n = 2333; r = 0.48; P .001). In placebo-treated patients at 2 years, the percentage of change from baseline in walking speed was significantly correlated with the change from baseline in SF-36 PCS score (r = 0.35; P .001). Significant correlations between the change in SF-36 PCS scores and the percentage of change in walking speed at 2 years also were observed in groups receiving active treatment (r, 0.13-0.28; P ≤ .005). Among placebo-treated patients, 27.5% had a clinically meaningful worsening (≥ 5-point decrease) in SF-36 PCS scores during the 2 years. Walking speed declined by 21.8% in these patients after 2 years, but only by 5.4% in those without worsening of SF-36 PCS scores.In patients with MS, walking speed measured using the T25-FW correlated with SF-36 PCS scores such that a decline in walking speed of 20% to 25% corresponded to a clinically meaningful worsening of SF-36 PCS scores. A 20% to 25% decline in walking speed may be a clinically meaningful threshold for defining worsening using the T25-FW in MS clinical trials and for monitoring patients in clinical settings. |
| تدمد: | 2168-6149 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3469bd13eb270060655368c3ffca0dabTest https://doi.org/10.1001/jamaneurol.2014.1895Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3469bd13eb270060655368c3ffca0dab |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21686149 |
|---|